Literature DB >> 16206294

Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution.

Daisuke Nonaka1, Shigeki Kusamura, Dario Baratti, Paolo Casali, Antonello Domenico Cabras, Rami Younan, Juan Rosai, Marcello Deraco.   

Abstract

BACKGROUND: In the current study, the authors report the clinicopathologic features of patients with peritoneal diffuse malignant mesothelioma (DMM) who were treated in a uniform fashion at a single institution to assess prognostic factors.
METHODS: Thirty-five patients were treated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). The tumors were classified into epithelial, sarcomatoid, and biphasic types. Immunohistochemistry stains were performed for calretinin, WT-1, pCEA, Ber-EP4, epidermal growth factor receptor (EGFR), p16, matrix metalloprotease-2 (MMP-2), and MMP-9. Statistical correlation was evaluated for age, gender, completeness of cytoreduction (CC), tumor histotype, mitotic count (MC), necrosis, nuclear grade (NG), and biologic markers with regard to overall survival (OS) and progression-free survival (PFS).
RESULTS: The patient group was comprised of 15 men and 20 women with a median age of 52 years (range, 24-73 yrs). Twenty-five patients underwent optimal cytoreduction. There were 32 epithelial tumors and 3 biphasic tumors, and 3 patients had an NG of 1, 19 had an NG of 2, and 13 had an NG of 3. The mean MC was 14.1 (range, 0-160 per 50 high-power fields). Necrosis was present in 11 cases. All the tumors were found to be positive for calretinin and WT-1 and were negative for pCEA and Ber-EP4. The NG and MC were found to be significantly associated with OS (P = 0.02 and P = 0.01, respectively) whereas CC was found to be associated with both OS (P = 0.05) and PFS (P = 0.03). No biologic markers were found to be of prognostic significance.
CONCLUSIONS: The results of the current study indicate that NG, MC, and CC may be useful prognostic factors in patients treated with CRS and IPHP. The expression of EGFR, MMP-2, and MMP-9 and absent and/or reduced expression of p16 in DMMs confirms the results of previous studies suggesting their role in tumor pathogenesis and kinetics. Copyright 2005 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16206294     DOI: 10.1002/cncr.21239

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  [Scoring systems for clinical staging of peritoneal carcinomatosis. A critical analysis].

Authors:  J Jähne; S Kübler
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

2.  Pathology of mesothelioma.

Authors:  Kouki Inai
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

3.  Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.

Authors:  David B Chapel; Jefree J Schulte; Gudrun Absenger; Richard Attanoos; Luka Brcic; Kelly J Butnor; Lucian Chirieac; Andrew Churg; Françoise Galateau-Sallé; Kenzo Hiroshima; Yin P Hung; Hedy Kindler; Thomas Krausz; Alberto Marchevsky; Mari Mino-Kenudson; Jeffrey Mueller; Kazuki Nabeshima; Kirin Turaga; Ann E Walts; Aliya N Husain
Journal:  Mod Pathol       Date:  2020-10-15       Impact factor: 7.842

4.  Experience with peritoneal mesothelioma at the Milan National Cancer Institute.

Authors:  Marcello Deraco; Dario Baratti; Antonello Domenico Cabras; Nadia Zaffaroni; Federica Perrone; Raffaella Villa; Jenny Jocollè; Maria Rosaria Balestra; Shigeki Kusamura; Barbara Laterza; Silvana Pilotti
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

5.  Malignant peritoneal mesothelioma.

Authors:  Stine Munkholm-Larsen; Christopher Q Cao; Tristan D Yan
Journal:  World J Gastrointest Surg       Date:  2009-11-30

Review 6.  Update on the management of malignant peritoneal mesothelioma.

Authors:  Paul H Sugarbaker
Journal:  Transl Lung Cancer Res       Date:  2018-10

7.  Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.

Authors:  Jason M Foster; Uppala Radhakrishna; Venkatesh Govindarajan; Joseph H Carreau; Zoran Gatalica; Poonam Sharma; Swapan K Nath; Brian W Loggie
Journal:  World J Surg Oncol       Date:  2010-10-13       Impact factor: 2.754

Review 8.  Peritoneal mesothelioma.

Authors:  Mary E Hesdorffer; John Chabot; Carolyn DeRosa; Robert Taub
Journal:  Curr Treat Options Oncol       Date:  2008-10-08

Review 9.  Advances in the management of peritoneal mesothelioma.

Authors:  Ali Raza; Wei-Ching Huang; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma.

Authors:  Aaron U Blackham; Edward A Levine
Journal:  European J Clin Med Oncol       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.